Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Glucagon Deficiency"'
Autor:
Patrick Gilon, Philippe Boudou, Fabrizio Andreelli, Michel Djibré, Pascal Ferré, Soraya Fellahi, Fidaa Ibrahim, Mathieu Boissan
Publikováno v:
Diabetes & metabolism, Vol. 47, no. 3, p. 101170 [1-3] (2021)
A non-diabetic chronic alcoholic and undernourished male patient [body mass index (BMI): 16.6 kg/m2] was admitted to our hospital emergency department. He had fasted for the previous 3 days. His blood lactate and ketone body concentrations were massi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6dc9e74d4a2d074eedb4268aab81dd5
https://hdl.handle.net/2078.1/230664
https://hdl.handle.net/2078.1/230664
Autor:
Yoshitaka Hayashi, Yusuke Seino
Publikováno v:
Journal of Diabetes Investigation
Both glucagon and glucagon‐like peptide‐1 (GLP‐1) are produced from proglucagon through proteolytic cleavage. Blocking glucagon action increases the circulating levels of glucagon and GLP‐1, reduces the blood glucose level, and induces the pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c27c125002a623b3c6646af288596185
https://pubmed.ncbi.nlm.nih.gov/29314731
https://pubmed.ncbi.nlm.nih.gov/29314731
Autor:
Francisco Javier Escalada
Publikováno v:
Medicina Clínica. 143:2-7
The hormone glucagon-like peptide-1 (GLP-1) is synthesized and secreted by L cells in the small intestine in response to food ingestion. After reaching the general circulation it has a half-life of 2-3 minutes due to degradation by the enzyme dipepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d20d40b8f7ee602d90275253566f434d
https://doi.org/10.1016/s0025-7753(14)70101-0
https://doi.org/10.1016/s0025-7753(14)70101-0
Autor:
Michael Scott, Randy J. Seeley, David A. D'Alessio, Darleen A. Sandoval, Stephanie Sisley, Ruth Gutierrez-Aguilar
Publikováno v:
Journal of Clinical Investigation. 124:2456-2463
Glucose control and weight loss are cornerstones of type 2 diabetes treatment. Currently, only glucagon-like peptide-1 (GLP1) analogs are able to achieve both weight loss and glucose tolerance. Both glucose and body weight are regulated by the brain,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e160595331b2522662f8ee4f5b3a5090
https://doi.org/10.1172/jci72434
https://doi.org/10.1172/jci72434
Autor:
Jeff Unger
Publikováno v:
Current Diabetes Reports. 13:663-668
Clinicians and patients are rapidly adapting GLP-1 receptor agonists as efficacious and safe therapeutic options for managing type 2 diabetes (T2DM). GLP-1 receptor agonists stimulate insulin production and secretion from the pancreatic β cells in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a054e334d6009b706898e2b33d04113c
https://doi.org/10.1007/s11892-013-0404-x
https://doi.org/10.1007/s11892-013-0404-x
Autor:
Fabrizio Thorel, Alvin C. Powers, Nicolas Damond, Patricia M Vuguin, Pedro Luis Herrera, Julie S. Moyers, Maureen J. Charron
Publikováno v:
eLife, Vol 5 (2016)
eLife, Vol. 5 (2016)
eLife, Vol. 5 (2016)
Glucagon secretion dysregulation in diabetes fosters hyperglycemia. Recent studies report that mice lacking glucagon receptor (Gcgr-/-) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-producing β-cells. Here, we s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8ff342c0f668f18a0c5a7dd70fda03b
https://doi.org/10.7554/elife.13828
https://doi.org/10.7554/elife.13828
Autor:
Yoshitaka Hayashi
Publikováno v:
Diabetes, Obesity and Metabolism. 13:151-157
Multiple bioactive peptides are produced from proglucagon encoded by glucagon gene (Gcg). Glucagon is produced in islet α-cells through processing by prohormone convertase 2 (Pcsk2) and exerts its action through the glucagon receptor (Gcgr). Althoug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a7fe27df66178fc8c853772de60673
https://doi.org/10.1111/j.1463-1326.2011.01456.x
https://doi.org/10.1111/j.1463-1326.2011.01456.x
Autor:
Hiromichi Maeda, Kazuhiro Hanazaki
Publikováno v:
Pancreatology. 11:268-276
The loss of pancreatic parenchyma resulting from pancreatic resection causes an extreme disruption of glucose homeostasis known as pancreatogenic diabetes. This form of glucose intolerance is different from the other forms of diabetes mellitus in tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bcf1b38bf7e5c4fd814340b9ed8d225
https://doi.org/10.1159/000328785
https://doi.org/10.1159/000328785
Autor:
Jens J. Holst, Kristine J. Hare, Carolyn F. Deacon, Filip K. Knop, Tina Vilsbøll, Meena Asmar
Publikováno v:
Diabetes
BASE-Bielefeld Academic Search Engine
BASE-Bielefeld Academic Search Engine
OBJECTIVE Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function, while the inhibition of α-cell secretion has received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cbcbcfe80efb752ff14c393fde7cff
https://doi.org/10.2337/db09-1414
https://doi.org/10.2337/db09-1414
Publikováno v:
Diabetologia. 53:730-740
Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glucose control in animals and humans with type 1 diabetes. However, there is little information on the role of the GLP-1R in the immune system. We studied the role of the GLP-1R in immune fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac53cdcad566a6f77682a2a3c3440ace
https://doi.org/10.1007/s00125-009-1643-x
https://doi.org/10.1007/s00125-009-1643-x